InvestorsHub Logo
Followers 38
Posts 8623
Boards Moderated 1
Alias Born 03/01/2015

Re: None

Saturday, 12/29/2018 5:20:20 AM

Saturday, December 29, 2018 5:20:20 AM

Post# of 330206
We are going to stay the course and:

1. Immediately file the new 510(k) applications for musculoskeletal and post-operative pain.
2. File the 510(k) application for Allay and continue our research on migraines, over active bladder, pelvic and phantom pain.
3. Continue discussions with the 5-active major pharmaceutical potential marketing partners.
4. Complete our 8th country deal and aggressively support the seven existing countries with Mundipharma.
5. Continue our marketing support of the UK B. Braun same day hip and knee replacement program and detail healthcare professionals to write reimbursable prescriptions.
6. Focus on getting the new insole product on the market.
7. Fine tune our reimbursable sales and marketing to the VA, the military, nursing homes, and hospices patients.
8. Dispose of the SEC’s case tried by an Administrative Law Judge who in 50+ cases over eleven years never ruled against the SEC.
9. If necessary, we will get a knowledgeable healthcare investor, in the absence of a major marketing partner.

Thank you for your continued support.